Provenge Uses Body's Immune System to Fight Prostate Cancer

The FDA appears poised to approve a revolutionary new vaccine that could extend the life of prostate cancer patients with far fewer of the harsh side effects of traditional treatments such as surgery, radiation and chemotherapy. The vaccine, known as Provenge, was developed by Seattle-based Dendreon Corp. It stimulates the body's own immune system to fight cancer cells. Even though studies show relatively modest benefits to users -- men with advanced prostate cancer who took Provenge lived 4½...Full Story
Commenting on this article is closed.